Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a late-stage clinical biopharmaceutical company committed to the development of novel therapeutics aimed at improving immune cell trafficking and reversing immune suppression. The company's core focus is on treating rare diseases and conditions resulting from immune system dysfunction, including cancer and genetic primary immunodeficiency diseases.
X4’s lead clinical candidate, mavorixafor, is a selective, small-molecule antagonist of the chemokine receptor CXCR4. Designed as an oral, once-daily therapy, mavorixafor targets immune cell mobilization and has shown promising results in clinical trials. It is currently under priority review by the FDA for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare primary immunodeficiency. The company’s recent NDA submission is supported by positive results from the global, pivotal 4WHIM Phase 3 clinical trial, which demonstrated mavorixafor's ability to reduce infection rates and improve immune cell counts without serious adverse events.
In addition to mavorixafor for WHIM syndrome, X4 is advancing its pipeline with ongoing investigations for mavorixafor in chronic neutropenic disorders and other immunodeficiencies. The company has also initiated preclinical development of other CXCR4 antagonists, including X4P-002 and X4P-003, to address different properties and mechanisms within the immune system.
Headquartered in Boston, Massachusetts, with a research center in Vienna, Austria, X4 leverages its deep understanding of CXCR4 biology to innovate and bring transformative therapies to patients with limited treatment options. The company's mission is driven by a commitment to improve the lives of those affected by rare and severe immune diseases through rigorous scientific research and strategic investment in its proprietary pipeline.
For more updates and detailed information, visit X4 Pharmaceuticals.
X4 Pharmaceuticals (XFOR) announced positive results from its completed six-month Phase 2 trial of mavorixafor in Chronic Neutropenia (CN). The study demonstrated that mavorixafor durably increased participants' mean absolute neutrophil counts (ANC) to normal levels. In combination therapy, it enabled substantial G-CSF dosing reductions (52% at Month 3 and 70% at Month 6) while maintaining normal ANC levels. A sub-study showed that neutrophils mobilized by mavorixafor were as functional as those from healthy donors. The drug was generally well tolerated with no drug-related serious adverse events reported.
X4 Pharmaceuticals (XFOR) has granted inducement awards to new employees under its 2019 Inducement Plan. The awards consist of options to purchase 271,764 shares of common stock at an exercise price of $0.5002 per share, equal to the closing price on October 31, 2024. The options have a ten-year term and will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (Nasdaq: XFOR) has announced it will report its third-quarter 2024 financial results and present findings from its completed Phase 2 clinical trial of mavorixafor in chronic neutropenia patients on November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. ET on the same day. The presentation will be accessible via phone and through the company's investor relations website, with a replay available afterward.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 744,468 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.6693 per share, equal to the closing price on September 30, 2024.
The options will vest over a four-year period, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining X4 Pharmaceuticals.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, granted on August 30, 2024, consist of options to purchase 230,588 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.70 per share, equal to the closing price of X4's stock on the grant date. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and was approved by X4's Compensation Committee.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on rare immune system diseases, has announced its participation in three major investor conferences in September 2024. These include:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
- Wells Fargo Healthcare Conference on September 5
- Cantor Fitzgerald Global Healthcare Conference on September 17
The company will engage in fireside chats and one-on-one meetings at these events. Live webcasts for the Morgan Stanley and Cantor Fitzgerald conferences will be available on X4's website, with replays accessible afterwards. Investors interested in one-on-one meetings should contact their respective conference representatives.
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q2 2024 financial results and corporate updates. Key highlights include:
1. First U.S. commercial sales of XOLREMDI™ (mavorixafor) following FDA approval in April 2024 for WHIM syndrome.
2. Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full results expected in November 2024.
3. Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia.
4. Recognized a $105 million gain from the sale of a priority review voucher.
5. Reported net income of $90.8 million for Q2 2024, compared to a net loss of $55.7 million in Q2 2023.
6. Cash position of $169.5 million as of June 30, 2024, expected to support operations into late 2025.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 708,236 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.8001 per share, equal to the closing price on July 31, 2024. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employees.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced its plans to report second quarter 2024 financial results and provide corporate updates on August 8, 2024. The company will host a conference call and webcast at 8:30 a.m. ET on the same day.
Investors and interested parties can access the conference call by dialing 1-800-225-9448 (US) or 1-203-518-9708 (international) with the conference ID: X4PHARMA. A live webcast will also be available through the investor relations section of X4 Pharmaceuticals' website. Following the call, a webcast replay will be accessible on the company's website.
X4 Pharmaceuticals has announced positive interim data from its ongoing Phase 2 trial of mavorixafor in chronic neutropenia (CN). The study showed that 100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increases with once-daily, oral mavorixafor, either alone or with stable-dose granulocyte colony-stimulating factor (G-CSF). Participants on mavorixafor monotherapy achieved durable mean ANC levels above the lower limit of normal for CN at Months 3 and 6. The company also initiated a pivotal Phase 3 trial named 4WARD to further evaluate mavorixafor's efficacy, safety, and tolerability in CN. The 52-week, randomized, double-blind, placebo-controlled study aims to enroll 150 participants globally.
FAQ
What is the current stock price of X4 Pharmaceuticals (XFOR)?
What is the market cap of X4 Pharmaceuticals (XFOR)?
What does X4 Pharmaceuticals specialize in?
What is mavorixafor?
What is WHIM syndrome?
What are the latest developments for X4 Pharmaceuticals?
What other conditions is mavorixafor being investigated for?
Where is X4 Pharmaceuticals headquartered?
Has mavorixafor received any special designations from regulatory bodies?
What are the promising indications from the 4WHIM Phase 3 clinical trial?
What other products are in X4 Pharmaceuticals' pipeline?
How can I stay updated on X4 Pharmaceuticals' progress?
